Global ECM Track: Recombinant Collagen, HA Injectables, and the Next Decade of dECM

Published: 2026/09/30  |  ECM Series · P5 (Finale)

One-sentence direct answer: The three major ECM-related tracks—recombinant collagen, HA injectable fillers, and dECM—are each at different stages of development: the China recombinant collagen market is surging from RMB 19.24 billion in 2022 to RMB 219.38 billion by 2030 at a CAGR of 44.93%, with 18 Class III certificates already clearing the regulatory path; HA injectable fillers represent USD 4.8–5.2 billion globally at a CAGR of 8–10%, with Asia-Pacific growth at 12.21% leading the way; dECM has just crossed over from wound dressings to medical aesthetics injectables, with NMPA's 2025 new classification introducing "micronized acellular dermal matrix," placing it in an early translation stage. All three tracks point toward the long-term direction of multi-component ECM synergy. (Sources: pmarketresearch, Frost & Sullivan, mordorintelligence, NIFDC)

I. Comparison of Market Size and Growth Rates Across Three Tracks

1.1 Recombinant Collagen

1.2 HA Injectable Fillers

1.3 dECM / Regenerative Medicine

As an independent market segment, dECM currently has no authoritative institution providing precise global market size figures. The field is in an accelerated phase of translation from laboratory to clinical application:

• Approved products: burn dressings (NMPA Registration No. 20193141514), MegaDerm (NMPA Class III, parotid isolation).
• 2025 NMPA new classification: "medical micronized acellular dermal matrix" for nasolabial fold filling, classified as Class III device.
• 3D bioprinting: collagen-based bioinks account for 63% of extrusion-based bioprinting trials (2023, Wake Forest Institute).

II. Regulatory Trends: Clarification of Three Pathways

2.1 Recombinant Collagen

NMPA issued the "Guiding Principles for the Naming of Recombinant Collagen Biomaterials," requiring product names to explicitly include the word "recombinant" and not to be conflated with animal-derived collagen. Classified as Class II/III devices based on use, with injectable fillers as Class III, and topical skincare products going through new cosmetic ingredient filing.

2.2 HA Injectable Fillers

Regulated as Class III medical devices, requiring full approval including clinical evaluation, biocompatibility, and long-term safety. Cross-linking technology is core—uncross-linked HA only lasts a few days in vivo, while cross-linked HA can last 6–18 months.

2.3 dECM

The 2025 NMPA new classification definition introduced "medical micronized acellular dermal matrix," marking dECM's strategic transition from wound repair to medical aesthetics injectables. Currently classified as Class III device, with no approved filler products yet.

2.4 New Cosmetic Ingredients

Recombinant collagen, low-molecular-weight HA, and others as cosmetic ingredients go through the new ingredient filing/registration pathway. After filing, they can be used in skincare products with claims limited to moisturizing, improving skin elasticity, etc.—medical efficacy claims are not permitted.

III. Technology Trends: From Single Components to Multi-Component ECM Synergy

3.1 Sequence Design and Modification of Recombinant Collagen

Leading companies have already made site-specific modifications based on human-derived sequences, such as enhancing specific receptor binding sites and improving thermal stability (Tm values approaching natural collagen at 40–42°C). Future directions include:

• Type-specific design (Type I vs Type III vs fusion type).
• Cross-linking technology to extend duration.
• Optimization of formulations combining with HA and peptides.

3.2 Precise Molecular Weight Control of HA

130 kDa showed optimal 20% elasticity improvement in RCTs, suggesting future formulations will more precisely control molecular weight distribution rather than simply pursuing "small molecules." The mechanism by which low-molecular-weight HA stimulates endogenous synthesis through the CD44/RHAMM→HAS-2 pathway will drive development of "signaling HA" ingredients.

3.3 Standardization and Scale-Up of dECM

The core challenges for dECM are batch consistency and scalable production. Future directions include:

• Standardization of decellularization processes (optimized combinations of physical/chemical/enzymatic methods).
• Quality control indicator systems (DNA residue, GAGs retention rate, growth factor activity).
• Combination of 3D bioprinting with dECM bioinks.

3.4 Multi-Component ECM Synergistic Formulations

The long-term direction for skincare and medical aesthetics products is to mimic the natural multi-component synergy of ECM: recombinant collagen (structure) + HA (hydration) + signaling peptides (cell communication) + antioxidants (protection). This "ECM combination" approach is closer to skin biology logic than simply stacking single ingredients.

IV. Product Selection Framework: How Brands Can Position in the ECM Track

4.1 Layering by Regulatory Pathway

4.2 Layering by Channel

• Consumer/retail channel: L1 cosmetics, featuring "ECM combination" formulations, with claims limited to moisturizing and improving elasticity.
• Professional/clinic channel: L1+L2, can combine medical dressings with skincare products, emphasizing professional endorsement.
• Medical aesthetics institutions: L3 injectable fillers, requiring Class III certificates, performed by licensed physicians.

4.3 The Group's Positioning in the ECM Track

The Group has sustained investment in recombinant collagen-related ingredients and product directions, holds Class II device registration certificates, and can provide OEM/ODM, beauty salon line customization, and franchise recruitment services to brands. Specific formulations and compliant claims must be executed according to product filing standards, and cross-tier claims are not permitted.

V. Risks and Uncertainties

5.1 Recombinant Collagen

• Possible tightening of Class III certificate approval: as application volume increases, NMPA may raise clinical requirements.
• Overcapacity risk: multiple companies expanding production, price wars may emerge in the next 3–5 years.
• Triple helix integrity controversy: product quality differences across expression systems still require long-term data validation.

5.2 HA Injectable Fillers

• Animal-derived replacement progress: fully synthetic formulations are growing faster, but animal-derived still holds 45% share, and the replacement path remains uncertain.
• Cross-linker safety: long-term safety of some cross-linkers (e.g., BDDE) remains controversial.

5.3 dECM

• Insufficient clinical data: no approved micronized dECM filler products yet, long-term safety and efficacy remain to be verified.
• Batch consistency: ensuring component consistency across different batches of dECM from natural tissue sources is a core challenge.
• Unclear regulatory pathway: approval standards, clinical endpoint design, etc. for dECM fillers have not yet been clarified.

Frequently Asked Questions (FAQ)